|
|
Дата |
|---|
| 23:00 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
11.90
|
12.02
|
12.20
|
11.84
|
12.34
|
11.95
|
|
|
484 127.43
|
297.00
|
|
11.13
|
13.50
|
12.10
|
12.00
|
12.69
|
12.19
|
|
|
465 526.98
|
316.00
|
|
11.43
|
13.05
|
14.38
|
12.25
|
14.38
|
12.625
|
|
|
640 344.35
|
353.00
|
|
11.13
|
17.08
|
13.76
|
13.09
|
13.875
|
13.47
|
|
|
600 436.92
|
285.00
|
|
11.12
|
17.08
|
12.59
|
12.59
|
14.23
|
14.23
|
|
|
424 707.75
|
200.00
|
|
12.61
|
13.07
|
12.70
|
12.235
|
13.09
|
12.69
|
|
|
878 292.30
|
301.00
|
|
10.94
|
13.07
|
12.69
|
12.04
|
13.14
|
12.40
|
|
|
546 388.37
|
302.00
|
|
10.93
|
17.08
|
11.50
|
11.475
|
12.565
|
12.45
|
|
|
313 915.84
|
173.00
|
|
4.73
|
12.08
|
12.51
|
11.41
|
12.67
|
11.72
|
|
|
170 828.15
|
164.00
|
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company. The Company is focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases with unmet medical need. Its lead product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson's disease (PD). It has the potential to be disease-modified by primarily replacing a patient's lost dopaminergic (DA) neurons with dopaminergic neuron precursor cells (DANPCs). The Company is leveraging its proprietary platform to build a diversified pipeline of autologous iPSC-based therapies for the treatment of multiple CNS diseases, with an initial focus on sporadic and genetic PD.
The Company is also conducting the open-label Phase 1/2a ASPIRO trial of a single dose of sasineprocel in mid-stage to moderately advanced PD patients.
Показать все Скрыть